ADMA Biologics Inc (ADMA) has disclosed a new risk, in the Regulation category.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ADMA Biologics Inc. faces significant business risks that could impact its stock value, as highlighted in their quarterly report. The summary of risk factors indicates that investing in their common stock is speculative due to various principal factors. These risks are detailed further in the report under ‘Risk Factors’ and should be reviewed alongside other information provided. Investors are advised to carefully consider these risks before making investment decisions.
Overall, Wall Street has a Moderate Buy consensus rating on ADMA stock based on 2 Buys.
To learn more about ADMA Biologics Inc’s risk factors, click here.